JO2999B1 - مركب ثلاثي حلقي و استخدامه الدوائي - Google Patents

مركب ثلاثي حلقي و استخدامه الدوائي

Info

Publication number
JO2999B1
JO2999B1 JOP/2007/0230A JOP20070230A JO2999B1 JO 2999 B1 JO2999 B1 JO 2999B1 JO P20070230 A JOP20070230 A JO P20070230A JO 2999 B1 JO2999 B1 JO 2999B1
Authority
JO
Jordan
Prior art keywords
pharmaceutical use
tricyclic compound
use therof
therof
tricyclic
Prior art date
Application number
JOP/2007/0230A
Other languages
English (en)
Inventor
Uchikawa Osamu
Koike Tatsuki
Takai Takafumi
Hoashi Yasutaka
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of JO2999B1 publication Critical patent/JO2999B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

يتعلق الاختراع الحالي بمركب (compound) متمثل في الصيغة : التي تكون مفيدة كعامل للوقاية من او معالجة امراض مرتبطة بتاثير الميلاتونين (melatonin)، او بملح (salt )،الخ.
JOP/2007/0230A 2006-06-19 2007-06-18 مركب ثلاثي حلقي و استخدامه الدوائي JO2999B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006168518 2006-06-19

Publications (1)

Publication Number Publication Date
JO2999B1 true JO2999B1 (ar) 2016-09-05

Family

ID=38519675

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2007/0230A JO2999B1 (ar) 2006-06-19 2007-06-18 مركب ثلاثي حلقي و استخدامه الدوائي

Country Status (36)

Country Link
US (5) US8030337B2 (ar)
EP (1) EP2029561B1 (ar)
JP (1) JP5222737B2 (ar)
KR (1) KR101442274B1 (ar)
CN (1) CN101506181B (ar)
AR (1) AR061478A1 (ar)
AU (1) AU2007261953B2 (ar)
BR (1) BRPI0713743C1 (ar)
CA (1) CA2655753C (ar)
CL (1) CL2007001779A1 (ar)
CO (1) CO6150175A2 (ar)
CR (1) CR10524A (ar)
CY (1) CY1115729T1 (ar)
DK (1) DK2029561T3 (ar)
ES (1) ES2523410T3 (ar)
GE (1) GEP20125392B (ar)
HK (1) HK1130049A1 (ar)
HR (1) HRP20141046T1 (ar)
IL (1) IL195639A0 (ar)
JO (1) JO2999B1 (ar)
MA (1) MA30523B1 (ar)
ME (2) ME00582A (ar)
MX (1) MX2008015842A (ar)
MY (1) MY158069A (ar)
NO (1) NO341739B1 (ar)
NZ (1) NZ574037A (ar)
PE (1) PE20080941A1 (ar)
PL (1) PL2029561T3 (ar)
PT (1) PT2029561E (ar)
RS (1) RS53616B1 (ar)
RU (1) RU2456278C2 (ar)
SI (1) SI2029561T1 (ar)
TW (1) TWI402261B (ar)
UA (1) UA99104C2 (ar)
WO (1) WO2007148808A1 (ar)
ZA (1) ZA200900151B (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica
KR20090095666A (ko) * 2006-12-28 2009-09-09 다케다 야쿠힌 고교 가부시키가이샤 삼환 화합물 및 이의 약학적 용도
CN103450111B (zh) * 2013-09-04 2015-07-08 温州大学 一种苯并噻唑杂环化合物的绿色合成方法
US20160253891A1 (en) * 2015-02-27 2016-09-01 Elwha Llc Device that determines that a subject may contact a sensed object and that warns of the potential contact
CA3010804A1 (en) * 2016-01-08 2017-07-13 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for autism spectrum disorder
KR20180100627A (ko) * 2016-01-08 2018-09-11 다케다 야쿠힌 고교 가부시키가이샤 섬망의 예방 또는 치료제
BR112019007964A2 (pt) 2016-10-19 2019-07-02 Monsanto Technology Llc composições e métodos para alterar a floração e arquitetura vegetal para aprimorar o potencial de rendimento

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292226C (en) * 1986-01-16 1991-11-19 Terumi Hachiya Indenothiazole derivative and process for preparing the same
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US6180657B1 (en) 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5654325A (en) 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
FR2725985B1 (fr) 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19502895A1 (de) 1995-01-31 1996-08-01 Merck Patent Gmbh 4-Mercapto-benzoylguanidin-Derivate
US5753709A (en) 1995-06-07 1998-05-19 Bristol-Myers Squibb Company N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
US5596019A (en) 1995-06-07 1997-01-21 Bristol-Myers Squibb Company N-acyl-cycloalkylamine derivatives as melatonergics
CA2176854A1 (en) 1995-06-07 1996-12-08 Daniel J. Keavy N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
FR2742153B1 (fr) 1995-12-12 1998-02-13 Innothera Lab Sa Utilisation de derives tricycliques du 1,4-dihydro-1,4- dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique
CN100441574C (zh) 1996-03-08 2008-12-10 武田药品工业株式会社 三环化合物及其制备和用途
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
SE9802360D0 (sv) * 1998-07-01 1998-07-01 Wikstroem Hakan Vilhelm New 2-aminothiazol-fused 2-aminoindans and 2-aminotetralins ((basic)-N-substituted and (basic)-N,N-disubstituted derivatives of 2,6-diamino-thiazolo(4,5-f)indan and 2,7-di-amino-thiazolo(4,5-g)tetralin
AU6595100A (en) * 1999-08-20 2001-03-19 Takeda Chemical Industries Ltd. Percutaneous absorption agents
WO2002040054A1 (fr) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Preparation pharmaceutique contenant de la copolyvidone
JP3633895B2 (ja) * 2000-11-17 2005-03-30 武田薬品工業株式会社 コポリビドン含有製剤
US6569894B1 (en) 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
US20050197365A1 (en) * 2004-02-27 2005-09-08 Jeffrey Sterling Diamino thiazoloindan derivatives and their use
US20060223877A1 (en) 2005-03-31 2006-10-05 Zemlan Frank P Methods of treatment utilizing certain melatonin derivatives
AR061478A1 (es) * 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica

Also Published As

Publication number Publication date
ME00582A (en) 2011-12-20
CO6150175A2 (es) 2010-04-20
MY158069A (en) 2016-08-30
US20140011849A1 (en) 2014-01-09
PT2029561E (pt) 2014-11-12
RU2456278C2 (ru) 2012-07-20
AU2007261953A1 (en) 2007-12-27
BRPI0713743A2 (pt) 2012-11-06
CL2007001779A1 (es) 2008-01-04
EP2029561A1 (en) 2009-03-04
PL2029561T3 (pl) 2015-03-31
ZA200900151B (en) 2010-03-31
US20110196003A1 (en) 2011-08-11
US8552037B2 (en) 2013-10-08
HRP20141046T1 (hr) 2014-12-19
AU2007261953B2 (en) 2012-11-08
CY1115729T1 (el) 2017-01-25
AR061478A1 (es) 2008-08-27
CN101506181B (zh) 2011-12-07
US20090182023A1 (en) 2009-07-16
IL195639A0 (en) 2009-09-01
US8030337B2 (en) 2011-10-04
NO341739B1 (no) 2018-01-15
US8236837B2 (en) 2012-08-07
RS53616B1 (en) 2015-04-30
US8349879B2 (en) 2013-01-08
BRPI0713743B8 (pt) 2020-05-19
CN101506181A (zh) 2009-08-12
MA30523B1 (fr) 2009-06-01
TWI402261B (zh) 2013-07-21
WO2007148808A1 (en) 2007-12-27
NZ574037A (en) 2011-10-28
KR20090023701A (ko) 2009-03-05
TW200815376A (en) 2008-04-01
US20130079374A1 (en) 2013-03-28
CA2655753C (en) 2015-08-04
ME01998B (me) 2015-05-20
US8895591B2 (en) 2014-11-25
KR101442274B1 (ko) 2014-09-22
HK1130049A1 (en) 2009-12-18
ES2523410T3 (es) 2014-11-25
JP5222737B2 (ja) 2013-06-26
MX2008015842A (es) 2009-01-09
NO20090234L (no) 2009-02-12
GEP20125392B (en) 2012-02-10
SI2029561T1 (sl) 2014-11-28
PE20080941A1 (es) 2008-09-04
US20110190361A1 (en) 2011-08-04
CA2655753A1 (en) 2007-12-27
CR10524A (es) 2009-01-27
DK2029561T3 (da) 2014-11-10
RU2009101299A (ru) 2010-07-27
EP2029561B1 (en) 2014-08-13
BRPI0713743B1 (pt) 2020-03-17
JP2009541202A (ja) 2009-11-26
BRPI0713743C1 (pt) 2021-05-25
UA99104C2 (uk) 2012-07-25

Similar Documents

Publication Publication Date Title
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
MX2010008460A (es) Derivado de tiazol y su uso como inhibidor de proteina-1 de adhesion vascular.
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
JO2848B1 (ar) مركبات عضوية
TNSN08283A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
TN2011000053A1 (en) Organic compounds
IN2012DN00869A (ar)
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
GEP20146125B (en) Aminopyrimidines as syk inhibitors
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
MY165579A (en) Synthetic methods for spiro-oxindole compounds
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
MX358961B (es) Compuestos de tetraciclina sustituidos con fluor en c7.
MX2009013353A (es) Compuestos activadores de telomerasa y metodos para su uso.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
TN2010000038A1 (en) Organic compounds
JO2581B1 (ar) سولفونوميدات أريل مستبدلة
JO2999B1 (ar) مركب ثلاثي حلقي و استخدامه الدوائي
IN2012DN02502A (ar)
MY152475A (en) Fused ring compounds and use thereof
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
UA103329C2 (ru) Соли соединений-ингибиторов вич
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
MA32945B1 (ar) تيتراهيدروبيران سبيرو بيروليدينون بيبيريدينون مستبدلة ، وإعدادها واستخدامها في العلاج